Expression of EZH2, a transcriptional target of MYCN, is associated with neuroblastoma outcome, and inhibition of this histone methyltransferase by genetic or pharmacologic means, leads to neuroblastoma growth inhibition43,44,52–54. Here, PRDM9 is linked to neuroblastoma.